Patents by Inventor Kin Chiu Fong

Kin Chiu Fong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide compound and application thereof, and composition containing peptide compound
    Patent number: 11981753
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound YA-156, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: May 14, 2024
    Assignee: ShangPharma Innovation Inc.
    Inventors: Yvonne Angell, Yu Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
  • COMPOUNDS AND THEIR USES AS MIF INHIBITORS
    Publication number: 20240083912
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Application
    Filed: October 27, 2023
    Publication date: March 14, 2024
    Inventors: Gouhuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • Compounds and their uses as MIF inhibitors
    Patent number: 11884682
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: January 30, 2024
    Assignee: NANJING IMMUNOPHAGE BIOTECH CO., LTD.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • Peptide compound and application thereof, and composition containing peptide compound
    Patent number: 11807660
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: November 7, 2023
    Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Yvonne Angell, Yu Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
  • Methods and Compositions for Targeting Tregs using CCR8 Inhibitors
    Publication number: 20230159446
    Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
    Type: Application
    Filed: December 23, 2022
    Publication date: May 25, 2023
    Inventors: Guohuang FAN, Hongyu YANG, Kin Chiu FONG, Jianfei WANG
  • Methods and compositions for targeting Tregs using CCR8 inhibitors
    Publication number: 20230038589
    Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
    Type: Application
    Filed: July 3, 2020
    Publication date: February 9, 2023
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Hongyu Yang, Kin Chiu Fong, Jianfei Wang
  • Isoquinolines as inhibitors of HPK1
    Patent number: 11566003
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: January 31, 2023
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • Peptide compound and application thereof, and composition containing peptide compound
    Patent number: 11427615
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 30, 2022
    Assignee: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Yvonne Angell, Yun Wu, Yan Wang, Weimin Liu, Kin Chiu Fong, Jie Wen, Yonghan Hu
  • PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND
    Publication number: 20220242908
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound YA-156, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Application
    Filed: April 22, 2022
    Publication date: August 4, 2022
    Inventors: Yvonne ANGELL, Yu WU, Yan WANG, Weimin LIU, Kin Chiu FONG, Jie WEN, Yonghan HU
  • PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND
    Publication number: 20220213142
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Application
    Filed: March 22, 2022
    Publication date: July 7, 2022
    Inventors: Yvonne ANGELL, Yu WU, Yan WANG, Weimin LIU, Kin Chiu FONG, Jie WEN, Yonghan HU
  • Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
    Publication number: 20220144838
    Abstract: The present invention provides compounds of Formula (I) shown below and their pharmaceutically acceptable salt, solvates, isomers, or prodrugs, as well as pharmaceutical compositions containing these compounds. Also provided by the invention is a method for treating a disorder mediated by macrophage migration inhibitory factor in a subject, comprising administering to the subject in need thereof a compound or a pharmaceutical composition of this invention.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO., LTD.
    Inventors: Kin Chiu FONG, Hongyu YANG, Ping DU, Jinfu YANG
  • CINNOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20220073520
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: March 26, 2021
    Publication date: March 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • COMPOUNDS AND THEIR USES AS MIF INHIBITORS
    Publication number: 20210403484
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 30, 2021
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • NAPHTHYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20210277024
    Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 9, 2021
    Applicant: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • ISOQUINOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20210253580
    Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Naphthyridines as inhibitors of HPK1
    Patent number: 11034692
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • ISOQUINOLINES AS INHIBITORS OF HPK1
    Publication number: 20210163417
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: July 6, 2020
    Publication date: June 3, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND
    Publication number: 20200172575
    Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.
    Type: Application
    Filed: July 5, 2018
    Publication date: June 4, 2020
    Applicant: XDCEXPLORER (SHANGHAI) CO., LTD.
    Inventors: Yvonne ANGELL, Yun WU, Yan WANG, Weimin LIU, Kin Chiu FONG, Jie WEN, Yonghan HU
  • Naphthyridines as inhibitors of HPK1
    Patent number: 10407424
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: September 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Blake Daniels, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca
  • Purine inhibitors of human phosphatidylinositol 3-kinase delta
    Patent number: 10221178
    Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 5, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth Ann McGowan, Hua Zhou, Jason D. Katz, Lihu Yang, Joey L. Methot, Kathryn Ann Lipford, Shimin Xu, Ning Fu, Guoquan Xu, Deqian Bian, Jianmin Fu, Yabin Li, Kin Chiu Fong